Description

Heron Therapeutics, Inc. is a biotechnology firm dedicated to developing innovative therapeutic solutions for significant unmet patient needs. At the heart of its pipeline is the proprietary Biochronomer drug delivery system. This technology enables the sustained release of various short-acting pharmacological agents, maintaining therapeutic levels for several days to weeks following a single administration. Currently available products include: SUSTOL (granisetron): An extended-release injectable formulated to prevent acute and delayed nausea and vomiting stemming from moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide regimens. CINVANTI (aprepitant): An intravenous antiemetic, acting as a substance P/neurokinin-1 receptor antagonist, used to prevent acute and delayed nausea and vomiting induced by both highly and moderately emetogenic cancer chemotherapy. Its robust development pipeline includes: ZYNRELEF: A dual-acting local anesthetic, delivering a fixed-dose combination of bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. HTX-019: An investigational therapeutic aimed at preventing postoperative nausea and vomiting. HTX-034: Currently in a Phase Ib/II clinical study with bunionectomy patients, designed for managing postoperative pain. Founded in 1983, the company initially operated as A.P. Pharma, Inc. before adopting the name Heron Therapeutics, Inc. in January 2014. Its corporate headquarters are situated in San Diego, California.